129 related articles for article (PubMed ID: 27191720)
1. Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression.
El Maassarani M; Barbarin A; Fromont G; Kaissi O; Lebbe M; Vannier B; Moussa A; Séité P
PLoS One; 2016; 11(5):e0155950. PubMed ID: 27191720
[TBL] [Abstract][Full Text] [Related]
2. ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF.
Andrique L; Fauvin D; El Maassarani M; Colasson H; Vannier B; Séité P
Cell Signal; 2012 May; 24(5):1074-85. PubMed ID: 22261253
[TBL] [Abstract][Full Text] [Related]
3. Expression and nuclear localization of ErbB3 in prostate cancer.
Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
[TBL] [Abstract][Full Text] [Related]
4. Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer.
Wang Z; Wu D; Ng CF; Teoh JY; Yu S; Wang Y; Chan FL
Endocr Relat Cancer; 2018 Jan; 25(1):35-50. PubMed ID: 29042395
[TBL] [Abstract][Full Text] [Related]
5. Annexin A1 promotes the nuclear localization of the epidermal growth factor receptor in castration-resistant prostate cancer.
Mota STS; Vecchi L; Alves DA; Cordeiro AO; Guimarães GS; Campos-Fernández E; Maia YCP; Dornelas BC; Bezerra SM; de Andrade VP; Goulart LR; Araújo TG
Int J Biochem Cell Biol; 2020 Oct; 127():105838. PubMed ID: 32858191
[TBL] [Abstract][Full Text] [Related]
6. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
7. Regulation of protein kinase C-related kinase (PRK) signalling by the TPα and TPβ isoforms of the human thromboxane A
O'Sullivan AG; Mulvaney EP; Kinsella BT
Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):838-856. PubMed ID: 28108419
[TBL] [Abstract][Full Text] [Related]
8. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
10. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
11. ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.
Wilzén A; Krona C; Sveinbjörnsson B; Kristiansson E; Dalevi D; Øra I; De Preter K; Stallings RL; Maris J; Versteeg R; Nilsson S; Kogner P; Abel F
Mol Cancer; 2013 Jul; 12(1):70. PubMed ID: 23835063
[TBL] [Abstract][Full Text] [Related]
12. Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells.
Koumakpayi IH; Le Page C; Delvoye N; Saad F; Mes-Masson AM
Mol Carcinog; 2011 Nov; 50(11):901-12. PubMed ID: 21438025
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
14. Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Wong N; Major P; Kapoor A; Wei F; Yan J; Aziz T; Zheng M; Jayasekera D; Cutz JC; Chow MJ; Tang D
Oncotarget; 2016 Dec; 7(50):83115-83133. PubMed ID: 27825118
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis.
Kim M; Lee HH; Won SD; Jang Y; Kim BG; Cho NH; Choi YD; Chung JS; Han HH
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276060
[TBL] [Abstract][Full Text] [Related]
16. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
17. Probing the prostate tumour microenvironment I: impact of glucose deprivation on a cell model of prostate cancer progression.
Tonry C; Armstrong J; Pennington SR
Oncotarget; 2017 Feb; 8(9):14374-14394. PubMed ID: 28086232
[TBL] [Abstract][Full Text] [Related]
18. PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castration-resistant prostate cancer-like cells.
Kang M; Lee KH; Lee HS; Park YH; Jeong CW; Ku JH; Kim HH; Kwak C
Prostate; 2016 Feb; 76(3):273-85. PubMed ID: 26499308
[TBL] [Abstract][Full Text] [Related]
19. Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.
Tonry C; Armstrong J; Pennington S
Oncotarget; 2017 Feb; 8(9):15307-15337. PubMed ID: 28410543
[TBL] [Abstract][Full Text] [Related]
20. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
